Möchten Sie immer auf dem neuesten Stand bleiben?

NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the...

NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A...

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global...

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following...

Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumorPivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented...

Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) --...

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC...

Royalty Receipts growth of 14% driving Portfolio Receipts of $717 millionNet cash provided by operating activities of $665 millionFull year 2024 guidance confirmed: Portfolio Receipts expected to be...

Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseasesExpands Royalty Pharma’s development-stage portfolio to...

NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S....